Novo Nordisk A/S (NVO)
Last Price$76.9(2.4%)
Market Cap$342.3B
NVO Rating
NVO Quality rating performance
NVO Intrinsic Value
Key Highlights:
As of Mar 21, 2025 NVO Relative Value is $63.9, which is overvalued by 16.9%, compared to current share price of $76.9.
As of Mar 21, 2025 NVO DCF Value is $80.0, which is undervalued by 4.1%, compared to current share price of $76.9.
NVO Share Price History
1W (0.4%)
1M (12.7%)
6M (37.9%)
YTD (24.1%)
1Y (40.3%)
3Y 43.4%
5Y 222.7%
10Y 255.5%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
NVO Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$342.3B
$353.4B
DKK 290.4B
DKK 70.0B
Shares Outstanding
4,454M
Employees
75K
Growth (CAGR)
18.9%
21.4%
6.72%
14.5%
24.6%
23.58%
Profitability
84.7%
44.3%
34.8%
41.7%
24.1%
69.4%
Intrinsic Value
$71.8 (6.5% overvalued)
$79.9
$63.8
49.0%
Return on Capital
Financial Health
DKK 26.3B
DKK 76.5B
1.1x
28.9x
71.6%
Dividends
DKK 9.9
20.7%
1.9%
63.0%
Mar 31, 2025
Earnings
Aug 06, 2025
BEAT by 4.6%
BEAT by 3.3%
(2.2%)
6 Beat & 4 Miss
NVO Stock Financials
NVO Income Statement Metrics
Annual
Quarterly
LTM
NVO Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$17.5B +11.1% YoY
Capital Expenditure (CAPEX)
($7,431.3M) +30.9% YoY
Free Cash Flow (FCF)
$10.1B +0.0% YoY
NVO Income Statement Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$42.1B 25.0% YoY
Cost of revenue
$6,448.3M 24.5% YoY
Pre-tax income
$18.4B 21.5% YoY
43.8% margin
NVO Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$64.5B
Current assets ($22.3B, 34.5% of total)
$3,641.0M (5.6%)
$12.1B (18.8%)
Other current assets
$6,529.0M (10.1%)
Non-current assets ($42.2B, 65.5% of total)
$370.5M (0.6%)
$22.5B (34.9%)
$12.6B (19.5%)
Other non-current assets
$6,741.0M (10.5%)
Financial position
$10.6B
Cash & Short-term
Investments
Total Debt
NVO Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
NVO Earnings Surprises
Crunching data... Almost there!
NVO Dividends
NVO Dividend Yield
Crunching data... Almost there!
NVO Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with NVO
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$342.3B | 7.1 | $71.8 6.5% overvalued | (40.3%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$756.9B | 7.0 | $225.5 73.1% overvalued | 9.4% | $45.0B | $510.8M | 32.0% | 1.1% | 81.6% | 40.7% | 235.7% | |
$393.8B | 6.0 | $196.9 20.3% undervalued | 8.4% | $88.8B | $18.1B | 4.3% | 20.3% | 69.1% | 15.7% | 51.2% | |
$370.7B | 6.0 | $301.2 43.4% undervalued | 22.6% | $56.3B | $17.8B | 3.7% | 31.7% | 73.6% | 8.3% | 1,996.0% | |
$236.6B | 7.5 | $112.8 21.1% undervalued | (23.1%) | $64.2B | $18.1B | 6.7% | 28.2% | 80.8% | 26.5% | 80.0% | |
$232.9B | 6.8 | $70.5 5.9% overvalued | 15.5% | $54.1B | $7,275.0M | 18.0% | 13.5% | 81.1% | 15.4% | 73.7% | |
$222.8B | 6.6 | $151.0 34.7% undervalued | 16.7% | $51.1B | $13.8B | 0.1% | 27.0% | 74.7% | 17.7% | 70.8% | |
$170.8B | 5.9 | $449.4 42.2% undervalued | 17.6% | $33.4B | $10.4B | 18.6% | 31.1% | 61.5% | 11.9% | 1,022.6% | |
$148.9B | 6.1 | $27.6 5.2% undervalued | 1.0% | $63.6B | $9,835.0M | 8.8% | 15.5% | 65.6% | 9.0% | 71.9% | |
$142.6B | 4.8 | $91.3 60.5% undervalued | 22.8% | €44.3B | (€504.0M) | (22.5%) | (1.1%) | 70.2% | 7.4% | 23.0% | |
$133.6B | 6.1 | $91.7 14.4% overvalued | 50.9% | $28.7B | $10.5B | 6.0% | 36.4% | 78.3% | 20.1% | 138.8% |
FAQ
What is Novo Nordisk A/S (NVO) stock rating?
As of today, Novo Nordisk A/S has a stock rating of 7 (out of 10), which is considered Great.
is Novo Nordisk A/S (NVO) a good stock to buy?
As of today, Novo Nordisk A/S has a Great stock rating, which is 6.5% overvalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 0.5%.